Features Partner Sites Information LinkXpress
Sign In
Demo Company

Data Mining HeData Mining Helps Detect Adverse Drug Reactions

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Print article
A new study suggests that information held in electronic medical records (EMRs) can validate previously reported adverse drug reactions (ADRs) and report new ones.

Researchers at the New Jersey Institute of Technology (NJIT; Newark, USA) examined 12 years of EMR data from Vanderbilt University Medical Center (VUMC; Nashville, TN, USA; www.mc.vanderbilt.edu) and reviewed retrospective medication orders and inpatient laboratory results documented in the EMR to identify ADRs. The researchers then assessed the relative merits of six pharmacovigilance measures used in spontaneous reporting systems: proportional reporting ratio (PRR), reporting OR (ROR), Yule's Q (YULE), the CHI-squared test, Bayesian confidence propagation neural networks (BCPNN), and a gamma Poisson shrinker (GPS).

The researchers then systematically evaluated the six methods on two independently constructed reference standard datasets of drug-event pairs. The first was the Yoon et al dataset, containing 470 drug-event pairs (10 drugs and 47 laboratory abnormalities). The second dataset was created using the VUMC EMRs, containing 378 drug-event pairs (9 drugs and 42 laboratory abnormalities). After evaluation, CHI, ROR, PRR, and YULE all had the same F score (62%). When the reference standard of Yoon et al was used, ROR had the best F score of 68%, with 77% precision and 61% recall. The study was published in the May 2013 issue of the Journal of American Medical Informatics Association.

“Medication safety requires that each drug be monitored throughout its market life as early detection of adverse drug reactions can lead to alerts that prevent patient harm,” said lead author computer scientist Mei Liu, PhD. “EMRs have created an unprecedented resource for observational studies since they contain not only detailed patient information, but also large amounts of longitudinal clinical data.”

Pharmacovigilance is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of ADRs, which are defined as any response to a drug, which is noxious and unintended, including lack of efficacy, which occurs at doses normally used for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. ADRs are one of the major causes for failure in drug development, and severe ADRs that go undetected until the postmarketing phase of a drug often lead to patient morbidity, as exemplified by numerous drug withdrawals.

Related Links:

New Jersey Institute of Technology

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.